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Plasma cells (PCs) are exposed to intense endoplasmic reticulum (ER) stress imposed 
by enormous rates of immunoglobulin (Ig) synthesis and secretion. Therefore, protein 
homeostasis is crucial for the survival of PCs, but its molecular mechanism remains 
largely unknown. Here, we found marked overexpression of FK506-binding protein 13 
(FKBP13) in long-lived PCs from autoimmune mice and investigated its function using 
a plasmacytoma cell line secreting IgA. FKBP13 expression was induced largely in the 
lumen of ER in response to treatment with an ER stressor tunicamycin or overexpression 
of an adaptive unfolded protein response (UPR) protein X-box binding protein 1 (XBP1). 
Silencing of FKBP13 expression led to induction of molecules involved in the terminal 
UPR and ER stress-associated apoptosis. FKBP13 interacted with Ig, facilitated its 
ubiquitination, and lowered the extent of ER stress. FKBP13 overexpression caused a 
significant reduction in secreted IgA in plasmacytoma cells, and FKBP13 knockdown 
exerted an opposite effect. Rapamycin interfered with the interaction between FKBP13 
and IgA and enhanced the amount of secreted IgA. Importantly, the level of FKBP13 
was inversely correlated with the amount of secreted antibody in long-lived PCs from 
autoimmune mice. These results suggest that FKBP13 is a marker of long-lived PCs and 
a component of XBP1-dependent ER protein homeostasis. FKBP13 is likely to act as a 
molecular chaperone that delivers misfolded ER clients, including Ig, to ER-associated 
degradation, so reducing proteotoxic stress on the PC. Our data reveal a novel cyto-
protective role for FKBP13 in long-lived PCs occurring at the expense of antibody 
production.
Keywords: plasma cells, long-lived plasma cells, FK506-binding protein 13, immunoglobulin, unfolded protein 
response, chaperone
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inTrODUcTiOn
Plasma cells (PCs) are the terminal effector cells of B lympho-
cytes, able to secrete copious amounts of antibodies [i.e., immu-
noglobulin (Ig) molecules], and thus constituting the humoral 
arm of adaptive immunity. PCs mostly die within 1 week in the 
secondary lymphoid organs where they develop. However, when 
PCs reside in milieu providing survival niches for them, such as 
bone marrow (BM) and inflamed sites, they terminally differenti-
ate into post-mitotic PCs attaining a life span of months or even 
decades (1). These long-lived PCs have been known to be crucial 
for long-lasting immunity in experimental animals and humans 
(2–6), but little is known about how they sustain viability for such 
a long period.
Owing to their enormous rates of Ig synthesis and secretion, 
PCs are exposed to intense stress imposed by the assembly and 
trafficking of the abundant Ig cargo through the endoplasmic 
reticulum (ER). ER stress readily activates the adaptive strategy 
known as the unfolded protein response (UPR) to sustain viability 
while restoring protein homeostasis (7). However, when the ER 
stress becomes excessive and so beyond the capacity of adaptive 
UPR, the terminal UPR is instead triggered and executes the apop-
totic program. The expression of the proapoptotic factor CHOP is 
a characteristic marker for terminal UPR leading to apoptosis (8). 
Several reports demonstrating the interplay between increased 
secretory load and ER stress-associated apoptosis in PCs suggest 
that long-lived PCs may be less sensitive to the latter (9, 10). 
However, the mechanism underlying how long-lived PCs evade 
ER stress-associated apoptosis remains largely unknown.
The UPR has three branches. Among these, the pathway medi-
ated by inositol-requiring enzyme 1 and its downstream player, 
X-box binding protein 1 (XBP1), is known to participate in PC 
differentiation (11, 12). In the absence of XBP1, B cells develop 
normally to the mature state but yield PCs that secrete reduced 
amounts of Igs (13). XBP1 predominantly functions to promote 
the expansion of the ER and so allow PCs to secrete copious 
levels of Igs (14). These effects largely depend on its activity as a 
transcription factor. The transcriptionally induced target genes of 
XBP1 produce molecular chaperones to enhance the capacity of 
protein folding and ER-associated degradation (ERAD). During 
ERAD, molecular chaperones protect unfolded or misfolded pro-
teins from spontaneous aggregation, facilitate their recognition by 
ubiquitin ligases, and finally deliver the ubiquitinated substrates 
to the proteasome (15). Thus, chaperones play a key role in the 
clearance of terminally misfolded proteins by the ubiquitin–pro-
teasome system (UPS). Although several chaperone molecules 
involved in the folding and assembly of Ig chains, such as BiP/
GRP78 and GRP94, have been characterized in B cells and PCs 
(16, 17), those important for protein homeostasis in long-lived 
PCs remain largely unexplored.
FK506-binding proteins (FKBPs) are a family of enzymes 
with peptidyl-prolyl cis-trans isomerase (PPIase, also known as 
rotamase) activity (18). In addition to this enzymatic activity, the 
PPIase domain contains a hydrophobic core that forms a drug-
binding pocket, which allows FKBP to serve as an immunophilin. 
Among 15 mammalian FKBPs known to date, the prototypical 
member FKBP12 is the only one that has been shown to form 
complex with FK506 and rapamycin in the cytosol and mediate 
their immunosuppressive effects in T cells (19, 20). FK506–
FKBP12 and rapamycin–FKBP12 complexes specifically inhibit 
calcineurin and mammalian target of rapamycin (mTOR), respec-
tively. FK506-binding protein 13 (FKBP13) shares with FKBP12 
approximately 43 and 51% homology at the levels of nucleotide 
and amino acid sequence, respectively (21). The conserved amino 
acid residues that comprise the drug-binding site of FKBP12 are 
completely conserved in FKBP13 (21). Nevertheless, the FK506–
FKBP13 complex did not significantly inhibit calcineurin in vitro 
(22), and no function of a rapamycin–FKBP13 complex in a cell 
has been reported to data. It has been shown that FKBP13 is 
located in the lumen of the ER in canine pancreatic cells and is 
induced by ER stressors in Madin–Darby canine kidney cells (23, 
24). However, whether FKBP13 plays an important role in PCs 
remains unknown to date.
Here, we investigated the role of FKBP13 in the UPR, apoptosis, 
and Ig production through the ER in PCs. We show that FKBP13 
are more abundant in the ER of long-lived PCs compared to 
short-lived PCs and plays an essential role in the quality control of 
Ig in the ER. This proteostatic mechanism may contribute to the 
sustained survival of long-lived PCs at the expanse of secretory 
Ig production.
MaTerials anD MeThODs
Plasmids and reagents
pcDNA3.1, pcDNA-sXBP1 (25), pcDNA-CHOP (26), pGL3b-
UPRE (carrying five copies of the UPRE domains) (27), and 
pRL-CMV (Promega) were used. Mouse FKBP13 cDNA was 
reverse-transcribed from RNA of RAW264.7 cells and inserted 
into MigR1 vector with myc tagging sequences (MigR1-myc-
FKBP13). Plasmids carrying DNA sequences encoding shRNA 
specific for FKBP13 (pGFP-V-RS-shFKBP13) or scrambled 
shRNA (pGFP-V-RS-SCR) were purchased from Origene. 
Rapamycin, LPS, and PMA were obtained from Sigma-Aldrich 
and MG-132 from Millipore.
Mice and Flow cytometry
All animal experiments were performed in strict accord-
ance with the recommendations in the Guide for the Animal 
Experimentation Ethics Committee of Hanyang University. 
The protocol was approved by the Institutional Animal Care 
and Use Committee of Hanyang University (permit numbers: 
HY-IACUC-16-0039 and HY-IACUC-16-0042). All methods 
were carried out in accordance with the guidelines and regulations.
NZB and NZW mice purchased from the Jackson Laboratory 
were crossed in a specific pathogen-free barrier facility at Hanyang 
University to obtain NZB/W F1 mice. KRN TCR transgenic mice 
on a C57BL/6 background (28) originally donated by Dr. Diane 
Mathis (Harvard Medical School, Boston, MA, USA) were kept 
in our animal facility and crossed with non-obese diabetic (NOD) 
and scurfy (Foxp3sf) mice to generate K/BxN and K/BxNsf strains, 
as described previously (29). Sanroque (Roquinsan/san) mice (30) 
were purchased from Mutant Mouse Regional Resource Center 
and bred in our animal facility.
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NZB/W F1 (36- to 40-week-old females), K/BxN (10-week-
old males), K/BxNsf (4-week-old males), and sanroque (19- to 
23-week-old) mice were fed drinking water containing 0.8 mg/
ml bromodeoxyuridine (BrdU) (Sigma-Aldrich) for 14  days 
and assayed as described previously (29). In some experiments, 
sanroque mice were injected intraperitoneally with rapamycin 
dissolved in 1% ethanol and resuspended in 0.2% carboxymethyl-
cellulose (Sigma-Aldrich) at a dose of 10 mg/kg of body weight/
injection every 2 days for 14 days.
Fluorochrome-conjugated monoclonal antibodies to B220, 
CD138, BrdU, and IgG1 were purchased from eBiosciences or BD 
Biosciences. Anti-FKBP13 antibody (Santa Cruz) was conjugated 
with phycoerythrin (PE), according to the manufacturer’s instruc-
tions (Solulink). In brief, succinimidyl-4-formylbenzamide 
linker was conjugated with R-PE to produce preactivated, highly 
fluorescent R-PE. The antibody was incubated with succinimidyl-
6-hydrazino-nicotinamide linker and then with preactivated 
R-PE in the presence of the TurboLink catalyst, leading to con-
version of the antibody to conjugate through formation of stable 
bis-arylhydrazone bonds.
cell culture and Transfection
J558 and BCL1 strains were purchased from ATCC, and M12.4.1 
cells (31) were provided by Dr. Mark Boothby (Vanderbilt 
University, Nashville, TN, USA). J558 cells were cultured with 
DMEM (Welgene, Daegu, South Korea) supplemented with 10% 
horse serum (Welgene) and penicillin/streptomycin (Welgene). 
One million cells were transfected with 5 μg DNA by electropora-
tion using Neon transfection system (Thermo Fisher Scientific) or 
NEPA21 Super Electroporator (Nepa Gene). Transfection efficiency 
was about 10–20%. Sixteen hours after transfection, the cells were 
harvested and subjected to further experiments. Cell viability was 
measured by the trypan blue exclusion method. To detect cell 
death, cells were stained with 7-aminoactinomycin D (7-AAD) and 
Annexin V (BD Biosciences) and assayed by flow cytometry.
immunocytochemistry
J558 cells were treated with 10 μg/ml tunicamycin (Tm) or DMSO 
for 48  h. The cells were plated on coverslips coated with poly-
l-lysine (Sigma-Aldrich) for 1 h, fixed with 4% paraformaldehyde 
in PBS for 15 min, and permeabilized with 0.5% Triton X-100 in 
PBS for 15 min. After blocking with 2% bovine serum albumin in 
PBS for 1 h, the cells were incubated with a mixture of goat anti-
FKBP13 (Santa Cruz) and mouse anti-KDEL antibodies (Abcam) 
for 2 h and then with a mixture of anti-goat IgG conjugated with 
Alexa Fluor 555 and anti-mouse IgG conjugated with Alexa Fluor 
488 (Thermo Fisher Scientific). Cells were washed with PBS three 
times between steps. The coverslips were mounted on slides using 
VECTASHIELD Hardset Antifade Mounting Medium with 
DAPI (Vectorlabs). Fluorescence images were visualized using a 
confocal microscope (Zeiss LSM 700) and analyzed using ZEN 
2012 SP2 (blue edition, ver.1.1.2.0).
immunoprecipitation and Western Blot 
analysis
Cells were incubated with RIPA buffer (GenDEPOT) containing 
a mixture of protease inhibitors and phosSTOP (all from Roche) 
on ice and spun down to obtain lysates. Forty  μg aliquots of 
lysates were assayed by SDS-PAGE and western blotting. Proteins 
were electrotransferred to Immobilon-P membranes (Millipore). 
For immunoprecipitation, cells were lysed with Xpro IP cell lysis 
buffer (GenDEPOT) containing a mixture of protease inhibitors 
(Roche). One mg of lysate was incubated with 1 μg of primary 
antibody or normal goat IgG overnight at 4°C, and then another 
overnight after adding 10 μg of protein G-agarose beads (Santa 
Cruz). Beads were washed and assayed by SDS-PAGE and west-
ern blotting. Anti-caspase-3 and anti-ubiquitin antibodies were 
purchased from Cell Signaling. Anti-FKBP13, anti-PARP1/2, 
anti-β-actin, and anti-GAPDH antibodies were obtained from 
Santa Cruz and anti-mouse IgA antibody from Southern Biotech. 
In some experiments, cells were pretreated with 100 nM rapamy-
cin for 24 h before lysis.
Quantitative rT-Pcr
Total RNA was purified using Qiazol reagent (Qizgen). cDNA 
was synthesized using amfiRivert cDNA Synthesis Master Mix 
(GenDEPOT) and amplified by quantitative PCR using SYBR 
Green Master Mix (Thermo Fisher Scientific). Relative amounts 
of each gene transcript were normalized to the amounts of β2 
microglobulin or GAPDH transcripts. Primer sequences used 
were as follows: FKBP11 (GGTCATAGAACTCGGCCAAA and 
CAGCTCCACATCGTACTGCA), FKBP13 (TGACAGCAGCCT 
ACCACAGA and AGCTCCACCTCAAACACCAG), spliced 
XBP1 (sXBP1) (GAGTCCGCAGCAGGTG and GTGTCAGAG 
TCCATGGGA), XBP1 (AAGAACACGCTTGGGAATGG and 
ACTCCCCTTGGCCTCCAC), ATF4 (AACCTCATGGGTTCT 
CCAGCGA and CTCCAACATCCAATCTGTCCCG), CHOP 
(TGAAATTGGGGGCACCTATA and CTGCTCCTTCTCCT 
TCATGC), Cα (TAACATGGACCAAGGTGCCC and GTTTG 
CTCCAGTAGCTGGGT), EDEM1 (GCTGCGTATCAGAGCA 
TCCAGA and CAGCGAGTCAATCCAGGTGTTC), EDEM2 
(GACCCTGTGTTTGAAGATGTGGC and CACTTGCCAGTG 
AGCACATCGA), Derl3 (GCAACTCGGTTGTCACAGACCT 
and CTGAGGGTCATCTAGTAGCAGC), Syvn1 (CCAACATC 
TCCTGGCTCTTCCA and CAGGATGCTGTGATAAGCGT 
GG), PDI (GTGTTGGAACTGACGGACGA and GGCAGTG 
CAATCCACCTTTG), BiP (CATGGTTCTCACTAAAATGAA 
GGA and GCTGGTACAGTAACAACTG), GRP94 (GTTTC 
CCGTGAGACTCTTCAGC and ATTCGTGCCGAACTCCTTC 
CAG), Blimp1 (ACCGTCTTGAGGACATGGAG and GTTGCT 
GTGAGGCAACTTCA), β2 microglobulin (TGACCGGCCTGT 
ATGCTATC and CAGTGTGAGCCAGGATATAG), and GAPDH 
(CATCACTGCCACCCAGAAGACTG and ATGCCAGTGAG 
CTTCCCGTTCAG).
enzyme-linked immunosorbent assays 
(elisa)
Sixteen hours after transfection of J558 cells with MigR1, MigR1-
myc-FKBP13, pGFP-V-RS, or pGFP-V-RS-shFKBP13, GFP-
positive cells were sorted using a FACS Aria III (BD Biosciences) 
and cultured in DMEM with 10% horse serum. After 48  h, 
supernatants were collected and assayed by sandwich ELISA to 
measure secreted IgA. In brief, immunosorbent plates (Thermo 
Fisher Scientific) precoated with 1.2 μg/ml goat anti-mouse IgA 
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were incubated with the spent media or serially diluted mouse 
IgA followed by anti-mouse IgA-HRP. All antibodies were pur-
chased from Southern Biotech.
luciferase assay
Cells transfected with MigR1, MigR1-myc-FKBP13, pGL4b, 
pGL3b-UPRE, and/or pRL-CMV were assayed with a Dual-
luciferase assay system (Promega). Firefly luciferase activity was 
normalized by Renilla luciferase activity and displayed as relative 
luciferase units.
statistical analysis
Data are presented as means ± SEMs. Differences between groups 
were evaluated by unpaired Student’s t-tests. Also, p values are 
indicated when differences between two groups were statistically 
significant (<0.05).
resUlTs
FKBP13 is a Marker of long-lived Pcs
We have previously shown that the vast majority of splenic PCs 
are short-lived in autoimmune arthritic K/BxN mice and long-
lived in K/BxNsf mice, the congenic strain carrying the scurfy 
allele (29). By using BrdU incorporation assays, we found that 
approximately 83% of the splenic PC populations in K/BxN 
mice were BrdU+ indicative of dividing, rapidly turning over 
cells, whereas approximately 90% of those in K/BxNsf mice were 
BrdU− long-lived cells that survived for at least 14 days without 
cell division (Figure 1A). To determine whether the difference 
in the life span between short-lived PCs and long-lived PCs cor-
relates to the folding capacity and UPR status of the ER, we sorted 
splenic PCs (B220loCD138+) from K/BxN and K/BxNsf mice and 
compared the expression of genes encoding molecules involved 
in the XBP1 branch of the UPR. The level of Xbp1 transcripts 
was higher in PCs from K/BxNsf mice than in those from K/
BxN mice. Transcripts encoding molecules with protein-folding 
capacity, such as PDI, BiP, and GRP94 (16, 17, 32), were also more 
abundant in PCs from K/BxNsf mice. The difference was more 
prominent for PDI transcripts and marginal for BiP and GRP94 
transcripts. Approximately 2.5- to 4-fold increases in K/BxNsf 
PCs were observed for ERAD components, such as EDEM1, 
EDEM2, and Derl3, but not Syvn (33). Interestingly, the tran-
scripts of two poorly characterized FKBP proteins, FKBP11 and 
FKBP13, were also more abundant in K/BxNsf PCs (Figure 1B). 
The upregulation of FKBP13 in K/BxNsf PCs was confirmed at 
the protein level (Figure 1C).
To determine whether FKBP13 is a general marker of long-
lived PCs, we carried out the same assays with F1 female hybrids 
of NZB and NZW strains (referred to hereafter as NZB/W F1), 
a canonical model of lupus and also known to have a substantial 
number of long-lived PCs in the spleen (SP) (34). Although the 
ratio of BrdU+ PCs to BrdU− PCs varied with the organ, FKBP13 
expression was invariably higher in BrdU− PCs than in their BrdU+ 
counterparts, regardless of organ (Figure  1D). These results, 
together with the data from K/BxNsf SPs, demonstrate that the 
levels of FKBP13 and protein-folding capacity are upregulated 
when PCs become long-lived.
FKBP13 is a component of XBP1-
Dependent er Protein homeostasis in 
long-lived Pcs
Because primary PCs mostly die spontaneously during in vitro 
culture, we needed a model cell line that mimics long-lived PCs 
to examine functional features of FKBP13 in vitro. To this end, 
we chose as a model cell line, the J558 murine plasmacytoma 
cell line, which at least partially mirrors the characteristics of 
long-lived PCs, such as secretion of monoclonal antibody and 
defects in apoptosis. J558 cells contained FKBP13 mRNA at a 
level higher than two lymphoma cell lines derived from murine 
mature B cells, M12.4.1 and BCL1 (Figure  2A). Interestingly, 
when BCL1 cells were stimulated with a mixture of LPS and 
PMA to induce the expression of Blimp1, the master regulator of 
PC differentiation, FKBP13 became more abundant (Figure 2B). 
This suggests that the expression of FKBP13 is induced during 
PC differentiation.
Since PCs require the XBP1-mediated pathway of UPR to 
maintain protein homeostasis, we tested whether FKBP13 is 
involved in this process using J558 cells. When the cells were 
treated with Tm to induce XBP1 expression, FKBP11 and FKBP13 
transcripts were elevated (Figure 2C). The induction of FKBP13 
was more prominent than that of FKBP11 and was confirmed at 
the protein level (Figure 2D).
To address whether the upregulation of FKBP13 in long-
lived PCs is functionally related to the homeostasis in the ER, 
we determined the intracellular localization of FKBP13 in J558 
cells. Although these cells in suspension culture were not an ideal 
model to analyze proteins’ intracellular distributions, immu-
nostaining analysis followed by confocal microscopy showed that 
FKBP13 marks specific subcellular compartments (Figure 2E). 
The staining pattern of FKBP13 was strikingly similar to that 
obtained by an antibody to the KDEL sequence, which marks 
ER lumen-residing proteins. These results suggest that FKBP13 
primarily localizes in the lumen of ER.
To address the functional relationship between XBP1 and 
FKBP13, J558 cells were transfected with cDNA encoding the 
spliced (i.e., active) form of XBP1 (sXBP1). The overexpression 
of sXBP1 markedly induced FKBP13, indicating that FKBP13 is 
a downstream target of XBP1 (Figure 2F). To further examine 
the function of FKBP13 in the ER homeostasis of long-lived 
PCs, we silenced FKBP13 mRNA by overexpression of specific 
shRNA (Figure 2G). FKBP13 silencing decreased the ratio of 
sXBP1 to total XBP1 (Figure 2H), suggesting that the expres-
sion of XBP1 and FKBP13 is tightly regulated by each other. 
These results suggest that FKBP13 is a component of XBP1-
dependent protein homeostasis in the ER of plasmacytoma 
cells.
FKBP13 silencing induces er stress-
associated apoptosis in Plasmacytoma 
cells
Various cellular stresses cause the accumulation of misfolded pro-
teins in the ER, triggering the UPR (7). During the early phase, 
the UPR increases the synthesis of folding factors to enhance 
protein-folding capacity and halts protein synthesis to reduce 
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FigUre 1 | enhanced expression of FK506-binding protein 13 (FKBP13) in long-lived plasma cells. (a) Splenocytes from K/BxN and K/BxNsf mice fed 
with bromodeoxyuridine (BrdU)-containing water for 14 days were examined by BrdU incorporation assays. FACS profiles gated on B220loCD138+ cells are shown. 
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significant.
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ER loading. However, if proteasomal inhibition prolongs, the 
UPR triggers so-called “ER stress-associated cell death” (35). To 
determine whether FKBP13 plays a role in ER stress-associated 
cell death in long-lived PCs, we silenced FKBP13 mRNA and 
examined the expression of UPS-associated proapoptotic tran-
scription factors, ATF4, and its downstream molecule CHOP. 
FKBP13 knockdown markedly induced the expression of ATF4 
and CHOP (Figure 3A). To confirm that CHOP is induced in 
the course of apoptosis, we overexpressed CHOP and monitored 
Annexin V+ cells using cell sorting analysis. The overexpression 
of CHOP markedly increased the frequencies of Annexin V+ 
7-AAD− early apoptotic and Annexin V+ 7-AAD+ late apoptotic 
cells (Figure  3B). Consistently, trypan blue exclusion assay 
showed that FKBP13 knockdown resulted in increased cell death 
in J558 plasmacytoma cells (Figure  3C), which correlated to 
upregulation of apoptotic markers, such as Annexin V positivity, 
caspase-3 cleavage, and PARP1/2 expression (Figures  3D,E). 
These results demonstrate that FKBP13 loss readily triggers ER 
stress-associated apoptosis in PCs.
FKBP13 has a role in Protein Quality 
control in the er of Plasmacytoma cells
To determine the role of FKBP13 in quality control of Ig, we 
performed coimmunoprecipitation assay between FKBP13 and 
Ig in J558 cells. We found that FKBP13 physically interacted with 
IgA molecules (Figure  4A), suggesting that FKBP13 acts as a 
molecular chaperone for incoming ER clients, such as Ig nascent 
polypeptides. FKBP13 was coimmunoprecipitated with goat IgG 
used as a negative control antibody, albeit to a much less extent 
than with anti-mouse IgA antibody (the first lane of Figure 4A), 
suggesting interaction between free FKBP13 and goat IgG in vitro. 
During the folding cycle in the ER lumen, terminally misfolded 
proteins are collected by molecular chaperones and delivered 
to the ERAD, in which the substrates are ubiquitinated by E3 
ubiquitin ligases and degraded by the proteasome (15, 16). We 
therefore asked whether FKBP13 is required for protein quality 
control in the ER. Notably, the overexpression of FKBP13 resulted 
in the accumulation of ubiquitin-conjugated protein species 
(Figure 4B). Such a trend was similarly observed when J588 cells 
FigUre 2 | continued
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FigUre 3 | FK506-binding protein 13 (FKBP13) silencing induces apoptotic death of plasmacytoma cells. (a,c–e) J558 cells were transfected with 
pGFP-V-RS-shFKBP13 (shFKBP13) or pGFP-V-RS-SCR (SCR). The cells were harvested 16 h after transfection and assayed by quantitative RT-PCR (a), trypan 
blue exclusion (c), FACS after staining with Annexin V and 7-aminoactinomycin D (7-AAD) (D), and immunoblotting (e). (B) J558 cells were transfected with 
pcDNA3.1 or pcDNA-CHOP (pCHOP) and assayed by quantitative RT-PCR for CHOP expression (left) and by FACS after staining with Annexin V and 7-AAD (right). 
All data are representative of more than three independent experiments. *p < 0.05 and **p < 0.01 by Student’s t-test.
FigUre 2 | continued 
FK506-binding protein 13 (FKBP13) is a component of the X-box binding protein 1 (XBP1) pathway of the unfolded protein response in 
plasmacytoma cells. (a) J558, M12.4.1, and BCL1 cells were assayed by quantitative RT-PCR methods to compare levels of FKBP13 transcripts. (B) BCL1 cells 
were treated with 10 μg/ml LPS plus 5 ng/ml PMA for 3 h, and levels of FKBP13 and Blimp1 mRNA were analyzed by quantitative RT-PCR. (c–e) J558 cells were 
treated with 10 μg/ml tunicamycin (Tm) or vehicle DMSO for 48 h, followed by quantitative RT-PCR (c), immunoblotting (D), and fluorescence microscopy after 
staining for FKBP13 (red) and KDEL (green) (e). Scale bars, 10 μm. (F) J558 cells were transfected with pcDNA3.1 or pcDNA-sXBP1 (sXBP1), incubated with 
0.8 mg/ml G418 for 24 h and assayed by quantitative RT-PCR. (g,h) J558 cells were transfected with pGFP-V-RS-shFKBP13 (shFKBP13) or pGFP-V-RS-SCR 
(SCR) and assayed by immunoblotting (g) and quantitative RT-PCR (h). sXBP1/tXBP1 indicates the ratio of spliced XBP1 to total XBP1. All data are representative 
of at least three independent experiments. *p < 0.05 and **p < 0.01 by Student’s t-test.
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were treated with the proteasome inhibitor MG132. Interestingly, 
the accumulated ubiquitin conjugates included IgA (Figure 4C). 
These results suggest that FKBP13 participates in quality control 
of ER clients, including Ig, possibly as a molecular chaperone that 
delivers terminally misfolded proteins to ERAD.
FKBP13 regulates the secretion of ig and 
counteracts er stress
Ubiquitination and degradation of Igs influence the amounts of 
secreted Ig molecules. To determine whether FKBP13 influences 
the secretion of functional Igs, we overexpressed FKBP13 in 
J588 cells and measured the amount of secreted IgA. FKBP13 
overexpression caused a significant reduction in secreted 
IgA (Figure  4D). Likewise, FKBP13 knockdown exerted an 
opposite effect, resulting in an increased amount of secreted 
IgA (Figure  4E). This effect is likely to take place at the post-
transcriptional level, because FKBP13 silencing did not alter the 
mRNA level of IgA heavy chain (Figure 4F).
Ubiquitination and degradation of surplus Igs reduce ER 
stress. To determine whether FKBP13 counteracts ER stress, we 
performed UPRE-luciferase assays using an XBP-1-dependent 
reporter construct. As shown in Figure 4G, FKBP13 overexpres-
sion dramatically lowered the XBP1-driven luciferase expression, 
i.e., the level of ER stress. This result indicates that FKBP13 
counteracts ER stress. Our results, taken together, suggest that 
FKBP13 acts as a chaperone targeting Ig molecules to the ubiqui-
tin-mediated degradation pathway. This proteostatic mechanism, 
functioning at the expense of Ig secretion, lowers ER stress to a 
level that does not trigger terminal UPR-mediated death.
rapamycin inhibits the activity of FKBP13 
in Plasmacytoma cells and Depletes 
long-lived Pcs in autoimmune Mice
Molecular chaperones recognize a stretch of hydrophobic 
amino acids exposed on the clients’ surface (15, 16). The PPIase 
domain of FKBP13 contains a hydrophobic core that forms a 
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drug-binding pocket. We speculated that the binding of rapa-
mycin to FKBP13 may interfere with FKBP13 interaction with 
Ig molecules and, thus, may inhibit the activity of FKBP13 as 
a molecular chaperone. To test this idea, we treated J558 cells 
with rapamycin for 24–48  h and immunoprecipitated IgA. 
Immunoblotting analysis showed that rapamycin reduced the 
amount of FKBP13 which is coimmunoprecipitated with IgA 
(Figure  5A). This result is consistent with the possibility that 
rapamycin blocks the hydrophobic core of the PPIase domain 
that also binds misfolded/unfolded amino acids of IgA. Next, we 
reasoned that if rapamycin indeed binds FKBP13 and inhibits 
its chaperone activity, rapamycin would enhance Ig production. 
Indeed, rapamycin-treated cells secreted more IgA as compared 
with untreated cells (Figure 5B). Although rapamycin was some-
what cytotoxic, inducing apoptosis (Figures 5C,D), these results 
together support our hypothesis that FKBP13 acts as a molecular 
chaperone for Igs in the ER lumen of PCs.
The sanroque mouse strain is a lupus model, in which hyper-
activation of follicular helper T cells precipitates autoantibody 
production and lupus nephritis (30). We found that, like NZB/W 
F1 mice, sanroque mice exhibit accumulation of long-lived PCs 
in their SP and lymph nodes (LN); approximately 36% of PC 
(B220loCD138+) population was BrdU− in BrdU incorporation 
assay (Figure 5E). To determine whether the effect of rapamycin 
is sufficient to deplete long-lived PCs in vivo, we treated sanroque 
mice with rapamycin for 2 weeks and measured remaining PCs. 
Treatment with rapamycin dramatically reduced the proportion 
of PCs by approximately 83%, suggesting a potential of rapamycin 
to deplete long-lived PCs.
antibody secretion is compromised in 
long-lived Pcs
The aforementioned data obtained from plasmacytoma cells 
suggest that FKBP13 is involved in the balance between Ig pro-
duction and the viability/longevity of PCs. We evaluated whether 
this trade-off exists in primary PCs. Splenic PCs from K/BxNsf 
mice, which were mostly long-lived and FKBP13hi, had lower 
levels of intracellular IgG1 than those from K/BxN mice, which 
were mostly short-lived and FKBP13lo (Figure 6A). In agreement 
with this, in NZB/W F1 mice labeled with BrdU for 2  weeks, 
BrdU− PCs in SPs, LN, BM, and salivary glands contained lower 
levels of intracellular IgG1 than BrdU+ PCs (Figure 6B). These 
results suggest that FKBP13 is involved in the trade-off between 
viability/longevity and antibody production in long-lived PCs.
FigUre 5 | effects of rapamycin on the functioning of FK506-binding protein 13 (FKBP13). J558 cells were cultured in the presence or absence of 100 nM 
rapamycin. (a) After 24 h, cells were assayed by immunoprecipitation methods. (B) After 24 or 48 h, the culture supernatants were assayed by enzyme-linked 
immunosorbent assays to determine the amounts of IgA secreted by 105 viable cells. (c) Cell viability was determined by trypan blue exclusion. (D) Cells were 
stained with 7-aminoactinomycin D (7-AAD) and Annexin V, followed by FACS analyses. All data are representative of three independent experiments. (e) Sanroque 
mice were fed with bromodeoxyuridine (BrdU)-containing water and injected with rapamycin for 2 weeks, followed by FACS analysis. Representative FACS profiles 
with percentages of cells within indicated areas and mean ± SEM (n = 2–3 mice/group) are shown. *p < 0.05 and **p < 0.01 by Student’s t-test. NS, not significant.
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DiscUssiOn
We have described here a novel function of FKBP13 in PCs that 
is distinct from their PPIase and immunophilin activities. Our 
study indicates that, as an XBP1-driven UPR protein, FKBP13 
chaperones surplus Ig molecules to the ubiquitin-mediated 
degradation system. As a result, PCs relieve ER stress and 
evade terminal UPR-mediated cell death. At the same time, the 
production of secretory antibodies is inevitably compromised. 
Thus, our results suggest that FKBP13 has a key role in the 
trade-off between viability and antibody production in long-
lived PCs.
How FKBP13 recognizes aberrant proteins remains to be 
elucidated. However, we hypothesize that the hydrophobic, 
drug-binding domain of FKBP13 selectively interacts with 
hydrophobic patches of unfolded proteins including nascent 
Igs that are not exposed in the native protein confirmation. Our 
finding that rapamycin interferes with the interaction between 
FKBP13 and Ig molecules strongly supports this hypothesis. By 
recognizing such aberrant sequences, FKBP13 may be able to 
deliver such protein cargos to the ubiquitin ligation system. In 
so doing, FKBP13 may form a transient network involving other 
chaperones and co-chaperones to orchestrate the complex tasks 
required. The detailed mechanisms underlying this process are 
currently under investigation.
Our data indicating the possibility of rapamycin–FKBP13 
binding is interesting since previous studies have exclusively 
pointed to cytosolic FKBP12 as a rapamycin-binding partner 
(20, 36). The rapamycin–FKBP12 complex is known to inhibit the 
mTOR pathway by directly binding to the mTOR complex 1 (37). 
We speculate that, just as the FK506–FKBP13 complex does not 
inhibit calcineurin (22), the rapamycin–FKBP13 complex does 
not directly inhibit the mTOR pathway, because its localization 
is restricted to the lumen of ER. Instead, rapamycin may deprive 
FKBP13 of the possibility to recognize and chaperone nascent 
Ig proteins. If this is the case, PCs may respond to rapamycin 
by two separate pathways—rapamycin–FKBP12–mTOR and 
rapamycin–FKBP13–UPS axes—that finally converge on the 
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FigUre 6 | compromised immunoglobin (ig) production in long-lived plasma cells. (a) Splenocytes from K/BxN and K/BxNsf mice were stained for B220, 
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pathway to cell death. Our data do not indicate which pathway 
contributes more to the cytotoxic effect of rapamycin in plasma-
cytoma cells. However, we noted with interest that expression of 
the two FKBPs is regulated in opposite directions by ER stress: 
FKBP12 expression was decreased and FKBP13 expression 
increased, in response to Tm (data not shown). In this regard, 
the action of rapamycin on FKBP13 chaperone function may be 
more important for perturbing the physiology of long-lived PCs 
under hyper-ER stress.
Although it is clear that FKBP13 expression is inversely 
correlated with the level of Ig secretion in PCs, the reduced anti-
body production seen in long-lived PCs is not necessarily due to 
FKBP13-mediated stimulation of ERAD, because PCs operate 
systems other than UPR, such as autophagy, for maintaining 
protein homeostasis (38). Autophagy engulfs cytoplasmic con-
tents and breaks down protein aggregates in double-membraned 
vesicles that are delivered to lysosome. Autophagy, if it occurs, 
may have a similar outcome to FKBP13-mediated ERAD, in 
terms of limiting Ig synthesis while sustaining viability. Indeed, 
the ERAD system is functionally connected to autophagy, since 
the ubiquitin system and chaperones are known to trigger 
autophagy (39). It would be worth seeing whether autophagy 
is more active in long-lived PCs than short-lived PCs in our 
system and whether FKBP13 can promote the initiation of 
autophagy.
We acknowledge that the cytotoxic effect of FKBP13 silenc-
ing was significant but not sufficient to deplete all plasmacy-
toma cells, perhaps due in part to the low efficiency of DNA 
delivery into plasmacytoma cells (usually 10–20%), which 
may lead to underestimating the effectiveness of FKBP13. It 
is also possible that other chaperones partially complement a 
deficiency of FKBP13. We suspect that FKBP11 can substitute 
for FKBP13, given that the PPIase domains of these two 
ER-resident proteins have 46% amino acid identity (22). Our 
data showing upregulation of BiP and GPR94 in long-lived 
PCs, albeit to modest extents, raise the question of whether 
these proteins cooperate with FKBP13 in targeting surplus 
Ig proteins to proteasomal degradation in long-lived PCs, 
in addition to their roles in the folding and assembly of Ig 
chains (40). Nevertheless, we have clearly demonstrated here 
that FKBP13 has a specific function in PCs not completely 
complemented by other chaperones.
The sustained presence of autoreactive long-lived PCs in 
peripheral lymphoid organs has the potential to exacerbate 
pathologic effects by several mechanisms. First, in addition 
to their continuous production of antibodies, these cells are 
refractory to immunosuppressive drugs, including steroids, 
cyclophosphamide, and rituximab (2, 3, 34). Second, they can 
become more active after B cell depletion therapy in some patients 
with autoimmune diseases (4, 5). Third, they evade immune 
complex-mediated cell death by downregulating the death 
receptor FcγRIIb (29). Finally, they promote the differentiation 
of follicular helper T cells, so forming a positive feedback loop 
that amplifies humoral immunity (6). Therefore, a strategy limit-
ing the longevity of these cells would be beneficial in controlling 
diseases related to long-lived PCs and plasmacytoma cells. Our 
data indicate that FKBP13 could be a novel therapeutic target for 
depleting pathogenic long-lived PCs.
In conclusion, we have identified FKBP13 as a key regulator of 
protein homeostasis in long-lived PCs. FKBP13 confers survival 
on PCs at the expense of antibody secretion. This insight into 
the mechanisms that control the viability of long-lived PCs and 
malignant PCs could lead to new strategies for treating autoim-
munity and myeloma.
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